{
    "nct_id": "NCT05221840",
    "official_title": "A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy",
    "inclusion_criteria": "INCLUSION CRITERIA:\n\n* Participant must be ≥ 18 years at the time of screening.\n* Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease\n* Provision of a tumour tissue sample obtained prior to CRT\n* Documented tumour PD-L1 status by central lab\n* Documented EGFR and ALK wild-type status (local or central).\n* Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy\n* Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy\n* Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.\n* WHO performance status of 0 or 1 at randomization\n* Adequate organ and marrow function\n\nEXCLUSION CRITERIA:\n\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.\n* Mixed small cell and non-small cell lung cancer histology.\n* Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.\n* Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.\n* Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).\n* Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.\n* History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.\n* Active or prior documented autoimmune or inflammatory disorders (with exceptions)\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}